TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.
Also called NCT04951050
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 200 participants
- Registry
-
NCT04951050
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04951050. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-08-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
- Acronym
- T-P
- Condition
- Coronary Artery Disease
- Condition
- Coronary Stenosis
- Intervention (Device)
- Rapamycin target eluting stent
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Record details
- Record id
cardio:ct-nct04951050- Content hash
d2d09ce7d555392c9d0d811e6e6cac753f284b5ad7641e27dd6cae2870663aa7